Table 2.
Results of the meta-analysis
| Outcomes | No. Studies | Sample size | Heterogeneity (P,I2) | Model | Overall effect size | 95% CI of overall effect | P | |
|---|---|---|---|---|---|---|---|---|
| LPD | OPD | |||||||
| Primary Outcomes | ||||||||
| POPF | 8 | 338 | 563 | 0.99, 0% | F | OR = 0.85 | 0.59~ 1.24 | 0.40 |
| Significant POPF | 5 | 271 | 512 | 0.96, 0% | F | OR = 0.86 | 0.53~ 1.41 | 0.56 |
| Morbidity | 7 | 280 | 505 | 0.37, 7% | F | OR = 0.57 | 0.41~ 0.78 | < 0.01 |
| Mortality | 8 | 1151 | 7934 | 0.98, 0% | F | OR = 0.88 | 0.64~ 1.20 | 0.41 |
| R0 rate | 11 | 1196 | 8247 | 0.97, 0% | F | OR = 1.17 | 1.00~ 1.37 | 0.05 |
| Retrieved lymph nodes | 10 | 1181 | 8233 | < 0.01, 86% | R | WMD = 1.15 | -0.16~ 2.47 | 0.08 |
| Overall survival | 6 | 1065 | 7867 | 0.31, 16% | R | HR = 1.02 | 0.93~ 1.13 | 0.66 |
| Secondary Outcomes | ||||||||
| Operation time (min) | 5 | 271 | 512 | < 0.01, 99% | R | WMD = 87.68 | 27.05~ 148.32 | < 0.01 |
| Blood loss (mL) | 5 | 271 | 512 | < 0.01, 96% | R | WMD = −197.49 | − 304.62~ − 90.37 | < 0.01 |
| Transfusion | 5 | 296 | 522 | 0.36, 7% | F | OR = 0.64 | 0.50~ 0.84 | < 0.01 |
| Hospital stay (days) | 9 | 1166 | 7948 | < 0.01, 85% | R | WMD = −1.07 | −3.05~ 0.92 | 0.29 |
| Tumor size | 10 | 368 | 862 | 0.46, 0% | F | WMD = −0.16 | −0.31~ − 0.02 | 0.03 |